Joseph Jacob, MD, MCR

Joseph Jacob, MD, MCR, SUNY Upstate Medical University

Articles by Joseph Jacob, MD, MCR

TAR-200 for BCG–Unresponsive High-Risk NMIBC CIS: 1-Year Durability, PROs

Joseph Jacob, MD, MCRUrothelial Carcinoma | April 28, 2025

Dr. Joseph Jacob shares the latest 1-year durability and PROs related to TAR-200 for BCG-unresponsive high-risk NMIBC.